Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 119
Filtrar
1.
Artigo em Espanhol | MEDLINE | ID: mdl-35597765

RESUMO

INTRODUCTION: Cardiovascular compromise in coronavirus disease 2019 (COVID-19) does not necessarily present with the classic symptoms described in myocarditis. There is growing evidence demonstrating subclinical cardiovascular compromise in the context of the intense inflammation unleashed, the cytokine storm involved, the baseline prothrombotic state, and the consequent endothelial dysfunction. We set out to analyse whether Troponin-T (TT) and the amino-terminal fraction of pro-brain natriuretic peptide (NT-proBNP) determined at hospital admission, are related to mortality during the hospitalization of these patients. MATERIAL AND METHODS: Analytical, observational, retrospective cohort and cross-sectional study. It included subjects with COVID-19 hospitalized for moderate-severe illness, from 20/03/20 to 15/11/20. The TT and NT-proBNP obtained in the first 24 hours from admission were analysed. Altered TT was considered if ≥.014 ng/dl and altered NT-proBNP if ≥300 pg/ml. RESULTS: One hundred and eight subjects were included, 63.2% men, age 51.5 years (59-43), 28% were admitted to the Critical Unit and 25% died. The group with elevated TT presented higher mortality (OR = 3.1; 95%CI = 1.10-8.85; p = .02). The group with elevated NT-proBNP also show higher mortality (OR = 3.47; 95%CI = 1.21-9.97; p = .01). On multivariate analysis, only NT-proBNP ≥300 pg/ml remained an independent risk factor. CONCLUSIONS: NT-proBNP levels ≥300 pg/ml at admission in patients with moderate-severe COVID-19 were associated with higher mortality.

3.
Arq. bras. cardiol ; 116(5): 928-937, nov. 2021. tab, graf
Artigo em Inglês, Português | LILACS | ID: biblio-1248895

RESUMO

Resumo Fundamento: Embora a elevação não isquêmica da troponina seja frequentemente observada em pacientes admitidos no pronto-socorro (PS), não há consenso quanto ao seu manejo. Objetivos: Este estudo teve como objetivo caracterizar os pacientes admitidos no PS com elevação da troponina não-isquêmica e identificar potenciais preditores de mortalidade nessa população. Métodos: Este estudo observacional retrospectivo incluiu pacientes do PS com resultado positivo no teste da troponina entre junho e julho de 2015. Pacientes com diagnóstico clínico de síndrome coronariana aguda (SCA) foram excluídos. Os dados demográficos dos pacientes e as variáveis clínicas e laboratoriais foram extraídos dos prontuários médicos. Os dados do seguimento foram obtidos por 16 meses ou até a ocorrência de morte. O nível de significância estatística foi de 5%. Resultados: A elevação da troponina sem SCA foi encontrada em 153 pacientes no PS. A mediana (IIQ) de idade dos pacientes foi de 78 (19) anos, 80 (52,3%) eram do sexo feminino e 59 (38,6%) morreram durante o seguimento. A mediana do período de seguimento (IIQ) foi de 477 (316) dias. Os sobreviventes eram significativamente mais jovens 76 (24) vs. 84 (13) anos; p=0,004) e apresentaram uma maior proporção de elevação da troponina isolada (sem elevação da creatina quinase ou mioglobina) em duas avaliações consecutivas: 48 (53,9%) vs. 8 (17,4%), p<0,001. Os sobreviventes também apresentaram menor taxa de tratamento antiplaquetário e internação no mesmo dia. Na regressão logística multivariada com ajuste para variáveis significativas na análise univariada, a elevação isolada da troponina em duas avaliações consecutivas mostrou hazard ratio = 0,43 (IC95% 0,17-0,96, p=0,039); hospitalização, tratamento antiplaquetário anterior e idade permaneceram independentemente associados à mortalidade. Conclusões: A elevação isolada da troponina em duas medidas consecutivas foi um forte preditor de sobrevida em pacientes no PS com elevação da troponina, mas sem SCA.


Abstract Background: Although non-ischemic troponin elevation is frequently seen in patients admitted to the emergency department (ED), consensus regarding its management is lacking. Objectives: This study aimed to characterize patients admitted to the ED with non-ischemic troponin elevation and to identify potential mortality predictors in this population. Methods: This retrospective observational study included ED patients with a positive troponin test result between June and July of 2015. Patients with a clinical diagnosis of acute coronary syndrome (ACS) were excluded. Data on patient demographics and clinical and laboratory variables were extracted from medical records. Follow-up data were obtained for 16 months or until death occurred. The statistical significance level was 5%. Results: Troponin elevation without ACS was found in 153 ED patients. The median (IQR) patient age was 78 (19) years, 80 (52.3%) were female and 59(38.6%) died during follow-up. The median (IQR) follow-up period was 477(316) days. Survivors were significantly younger 76 (24) vs. 84 (13) years; p=0.004) and featured a higher proportion of isolated troponin elevation (without creatine kinase or myoglobin elevation) in two consecutive evaluations: 48 (53.9%) vs. 8 (17.4%), p<0.001. Survivors also presented a lower rate of antiplatelet treatment and same-day hospitalization. In the multivariate logistic regression with adjustment for significant variables in the univariate analysis, isolated troponin elevation in two consecutive evaluations showed a hazard ratio= 0.43 (95%CI 0.17-0.96, p=0.039); hospitalization, previous antiplatelet treatment and age remained independently associated with mortality. Conclusions: Isolated troponin elevation in two consecutive measurements was a strong predictor of survival in ED patients with troponin elevation but without ACS.


Assuntos
Humanos , Masculino , Feminino , Idoso , Troponina I , Síndrome Coronariana Aguda/diagnóstico , Prognóstico , Biomarcadores , Serviço Hospitalar de Emergência , Hospitalização
4.
Rev. argent. cardiol ; 89(5): 462-465, oct. 2021. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1356924

RESUMO

RESUMEN Objetivos: Establecer la prevalencia de infarto agudo de miocardio (IAM) y otras etiologías en pacientes con troponina elevada, relacionar su valor con la etiología y definir el mejor punto de corte para diferenciar un IAM de otras causas. Material y métodos: Se incluyeron todos los pacientes con troponina elevada internados en un año e incorporados al registro REGIBAR. Para analizar la magnitud utilizamos el valor dosado más elevado/valor de referencia. Para establecer el mejor punto de corte se realizó curva ROC y el índice Youden. Resultados: Ingresaron 150 casos (edad: 66,3 ± 13,8 años, 71% hombres); 109 IAM (edad: 71,1 años, 63,5% masculinos), 18 (12%) otras causas cardiacas, 15 (10%) causas no cardíacas y en 8 (5,3%) no se obtuvo etiología. El mejor punto de corte troponina dosada/valor de referencia para discriminar IAM fue >3,15. Conclusiones: En pacientes hospitalizados con troponina elevada el 73% de los casos fue IAM (>3,15veces el punto de corte). La segunda causa más frecuente de elevación fue la insuficiencia cardíaca.


ABSTRACT Objectives: To determine the prevalence of acute myocardial infarction (AMI) and other etiologies in patients with elevated troponin, to associate troponin values with the etiology, and to define the optimal cut-off point to differentiate AMI from other causes. Methods: All patients with elevated troponin who were hospitalized within 1 year and registered in the REGIBAR study were included. Magnitude was analyzed with the highest dose value/baseline value. The ROC curve and the Youden index were used to determine the optimal cut-off point. Results: A total of 150 cases were included (age: 66.3 ± 13.8 years, 71% male); 109 AMI (age: 71.1 years, 63.5% male), 18 (12%) with other cardiac causes, 15 (10%) with non-cardiac causes, and 8 (5.3%) with no evident etiology. The optimal cut-off point for troponin dose/baseline value to discriminate AMI was >3.15. Conclusions: A 73% of inpatients with elevated troponin were AMI cases (>3.15 times the cut-off point). Heart failure was the second most common cause of elevated troponin.

5.
Endocrinol Diabetes Nutr (Engl Ed) ; 68(5): 321-328, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-34556262

RESUMO

AIM: The objective of this work was to define a value for the 99th percentile of high-sensitive troponin T and to evaluate the prognostic value of this biomarker in a population of patients with type 2 diabetes without a history of cardiovascular disease. METHODS: In this prospective, observational and analytic study, 482 patients with type 2 diabetes were enrolled. The patients were asymptomatic, with no history of cardiovascular events, renal insufficiency, or inflammatory or systemic disease. As events we considered a combined end point of major adverse cardiovascular events (MACE). RESULTS: 94.9% of the patients had detectable troponin values, 20.7% of the patients had troponin values above the healthy population reference upper threshold (14pg/mL). The 99th percentile value for this patient population was 48pg/mL. Age, sex, the glomerular filtration rate and hypertension were associated with troponin values>14pg/mL. The incidence of MACE was 3.96 per 100 patients/year (p/y) between those with hs-TnT>14pg/mL and 1.07 per 100 p/y between those with hs-TnT≤14pg/mL (HR=3.78 CI95 1.49-9.58; p=0.005). CONCLUSIONS: The 99th percentile value of troponin T in a population of patients with type 2 diabetes is 3-fold higher than the value proposed by the manufacturer for a healthy population. We also observed a significant difference in the distribution of troponin T values between men and women. This biomarker may be a valuable prognostic factor, since troponin T values above the reference upper threshold were associated with an increase in the risk of cardiovascular events in these patients.


Assuntos
Diabetes Mellitus Tipo 2 , Troponina T/sangue , Biomarcadores/sangue , Doenças Cardiovasculares/diagnóstico , Diabetes Mellitus Tipo 2/sangue , Feminino , Humanos , Masculino , Prognóstico , Estudos Prospectivos
6.
Rev Port Cardiol (Engl Ed) ; 40(9): 679-684, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34503707

RESUMO

INTRODUCTION: P-wave dispersion (PWD) and cardiac troponin levels are independently associated with the recurrence of atrial fibrillation (AF) in patients with paroxysmal AF (PAF). We investigated the clinical usefulness of combining PWD and cardiac troponin I to predict AF recurrence in patients presenting to the emergency department with PAF. METHODS: This study included 65 patients with PAF who were divided into three groups according to baseline troponin I and PWD values (group 1, troponin I<0.11 ng/dl and PWD<44.5 ms; group II, troponin I<0.11 ng/dl and PWD≥44.5 ms, or troponin I≥0.11 ng/dl and PWD<44.5 ms; group III, troponin I≥0.11 ng/dl and PWD≥44.5 ms). RESULTS: The AF recurrence rate was significantly higher in group III than in groups I and II. Multivariate analysis revealed that the troponin I and PWD values in group III (odds ratio: 7.236, 95% confidence interval: 1.879-27.861, p=0.004) were independent predictors of AF recurrence. CONCLUSIONS: The combined use of PWD and basal troponin I levels is a better predictor of AF recurrence than either value alone.


Assuntos
Fibrilação Atrial , Veias Pulmonares , Fibrilação Atrial/diagnóstico , Eletrocardiografia , Humanos , Recidiva , Troponina
8.
Med Clin (Barc) ; 157(4): 164-171, 2021 08 27.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-33958143

RESUMO

BACKGROUND: The outbreak of novel coronavirus pneumonia 2019 (COVID-19) has caused millions of deaths worldwide. It is well documented that troponin predicts the prognosis of patients. Myoglobin is not only an important marker of myocardial injury, but it indicates systemic muscle damage. However, its relationship with COVID-19 was rarely reported. The present study compared the predictive value of troponin and myoglobin on the final prognosis of COVID-19 patients by analyzing the clinical characteristics and serum levels of myoglobin and troponin in severe/critical COVID-19 patients. METHODS: We enrolled 499 consecutive eligible hospitalized patients with severe/critical COVID-19 from February 14 to March 24, 2020 at Leishenshan Hospital, Wuhan, China. Clinical characteristics and laboratory data were collected and compared between the patients who died and survived. We analyzed the receiver operating characteristic curves of myoglobin and troponin. Then, the patients were divided into myo+ group, myo- group, tro+ group, and tro- group, and survival curves were analyzed. The prognostic predictable values of myoglobin and troponin were further analyzed using Cox multifactorial analysis. RESULTS: Myoglobin and troponin were significantly elevated in the death group (134.4 [interquartile range (IQR) 24.80, 605] vs 38.02 [IQR 3.87, 11.73]ng/ml, p<0.001), and troponin was also significantly elevated in the death group (0.01 [IQR 0.01, 0.01] vs 0.04 [IQR 0.02, 0.15]ng/ml, p<0.001). The ROC curves demonstrated that the area under the curve when using myoglobin to predict patient death was 0.911, with a threshold of 1.17, which was equivalent to troponin. Kaplan-Meier survival analysis revealed a significantly lower survival curve in the myo+ group than the myo- group. Multifactor Cox survival analysis showed that troponin was no longer significant (HR=0.98, 95% CI 0.92-1.03, p=0.507), but elevated myoglobin was an independent predictor of death in COVID-19 patients (HR=1.001, 95% CI 1.001-1.002, p<0.001). The analysis of the Cox model for predicting patient death and plotting decision curves suggested that the single factor myoglobin model was superior to troponin, and the predictive value of the multifactor model was superior to the single-factor analyses. CONCLUSIONS: In severe/critical COVID-19 patients, myoglobin and troponin were predictors of mortality and the probability of conversion to critical illness, and myoglobin may be superior to troponin for predictive value.


Assuntos
COVID-19 , Mioglobina , Biomarcadores , Humanos , Prognóstico , Estudos Retrospectivos , SARS-CoV-2 , Troponina
9.
Med Clin (Barc) ; 157(6): 274-280, 2021 Sep 24.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-33846001

RESUMO

BACKGROUND: Myocardial injury has been identified as a common complication in patients with COVID-19. However, recent research has serious limitations, such as non-guideline definition of myocardial injury, heterogenicity of troponin sampling or very short-term follow-up. Using data from a large European cohort, we aimed to overcome these pitfalls and adequately characterize myocardial damage in COVID-19. METHODS: Consecutive patients with confirmed SARS-CoV-2 infection and available high-sensitive troponin I (hs-TnI), from March 1st to April 20th, 2020 who completed at least 1-month follow-up or died, were studied. RESULTS: A total of 918 patients (mean age 63.2±15.5 years, 60.1% male) with a median follow-up of 57 (49-63) days were included. Of these, 190 (20.7%) fulfilled strict criteria for myocardial injury (21.1% chronic, 76.8% acute non-ischemic, 2.1% acute ischemic). Time from onset of symptoms to maximum hs-TnI was 11 (7-18) days. Thrombotic and bleeding events, arrhythmias, heart failure, need for mechanical ventilation and death were significantly more prevalent in patients with higher hs-TnI concentrations, even without fulfilling criteria for myocardial injury. hs-TnI was identified as an independent predictor of mortality [HR 2.52 (1.57-4.04) per 5-logarithmic units increment] after adjusting for multiple relevant covariates. CONCLUSION: Elevated hs-TnI is highly prevalent among patients with SARS-CoV-2 infection. Even mild elevations well below the 99th URL were significantly associated with higher rates of cardiac and non-cardiac complications, and higher mortality. Future research should address the role of serial hs-TnI assessment to improve COVID-19 prognostic stratification and clinical outcomes.


Assuntos
COVID-19 , Insuficiência Cardíaca , Idoso , Biomarcadores , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , SARS-CoV-2 , Troponina I
11.
Endocrinol Diabetes Nutr (Engl Ed) ; 68(5): 321-328, 2021 May.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-33153945

RESUMO

AIM: The objective of this work was to define a value for the 99th percentile of high-sensitive troponin T and to evaluate the prognostic value of this biomarker in a population of patients with type 2 diabetes without a history of cardiovascular disease. METHODS: In this prospective, observational and analytic study, 482 patients with type 2 diabetes were enrolled. The patients were asymptomatic, with no history of cardiovascular events, renal insufficiency, or inflammatory or systemic disease. As events we considered a combined end point of major adverse cardiovascular events (MACE). RESULTS: 94.9% of the patients had detectable troponin values, 20.7% of the patients had troponin values above the healthy population reference upper threshold (14pg/mL). The 99th percentile value for this patient population was 48pg/mL. Age, sex, the glomerular filtration rate and hypertension were associated with troponin values>14pg/mL. The incidence of MACE was 3.96 per 100 patients/year (p/y) between those with hs-TnT>14pg/mL and 1.07 per 100 p/y between those with hs-TnT≤14pg/mL (HR=3.78 CI95 1.49-9.58; p=0.005). CONCLUSIONS: The 99th percentile value of troponin T in a population of patients with type 2 diabetes is 3-fold higher than the value proposed by the manufacturer for a healthy population. We also observed a significant difference in the distribution of troponin T values between men and women. This biomarker may be a valuable prognostic factor, since troponin T values above the reference upper threshold were associated with an increase in the risk of cardiovascular events in these patients.

12.
Rev Esp Cardiol (Engl Ed) ; 74(7): 576-583, 2021 Jul.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-33153955

RESUMO

INTRODUCTION AND OBJECTIVES: COVID-19 is currently causing high mortality and morbidity worldwide. Information on cardiac injury is scarce. We aimed to evaluate cardiovascular damage in patients with COVID-19 and determine the correlation of high-sensitivity cardiac-specific troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) with the severity of COVID-19. METHODS: We included 872 consecutive patients with confirmed COVID-19 from February to April 2020. We tested 651 patients for high-sensitivity troponin T (hs-TnT) and 506 for NT-proBNP on admission. Cardiac injury was defined as hs-TnT> 14ng/L, the upper 99th percentile. Levels of NT-proBNP> 300 pg/mL were considered related to some extent of cardiac injury. The primary composite endpoint was 30-day mortality or mechanical ventilation (MV). RESULTS: Cardiac injury by hs-TnT was observed in 34.6% of our COVID-19 patients. Mortality or MV were higher in cardiac injury than noncardiac injury patients (39.1% vs 9.1%). Hs-TnT and NT-proBNP levels were independent predictors of death or MV (HR, 2.18; 95%CI, 1.23-3.83 and 1.87 (95%CI, 1.05-3.36), respectively) and of mortality alone (HR, 2.91; 95%CI, 1.211-7.04 and 5.47; 95%CI, 2.10-14.26, respectively). NT-ProBNP significantly improved the troponin model discrimination of mortality or MV (C-index 0.83 to 0.84), and of mortality alone (C-index 0.85 to 0.87). CONCLUSIONS: Myocardial injury measured at admission was a common finding in patients with COVID-19. It reliably predicted the occurrence of mortality and need of MV, the most severe complications of the disease. NT-proBNP improved the prognostic accuracy of hs-TnT.


Assuntos
COVID-19 , Cardiopatias/virologia , Biomarcadores , COVID-19/complicações , COVID-19/diagnóstico , COVID-19/mortalidade , Humanos , Miocárdio/patologia , Peptídeo Natriurético Encefálico , Fragmentos de Peptídeos , Prognóstico , Respiração Artificial , Fatores de Risco , Troponina T
13.
Rev Esp Cardiol (Engl Ed) ; 74(1): 24-32, 2021 Jan.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-33144126

RESUMO

INTRODUCTION AND OBJECTIVES: Cardiac troponin, a marker of myocardial injury, is frequently observed in patients with COVID-19 infection. Our objective was to analyze myocardial injury and its prognostic implications in patients with and without COVID-19 infection treated in the same period of time. METHODS: The present study included patients treated in a university hospital with cardiac troponin I measurements and with suspected COVID-19 infection, confirmed or ruled out by polymerase chain reaction analysis. The impact was analyzed of cardiac troponin I positivity on 30-day mortality. RESULTS: In total, 433 patients were distributed among the following groups: confirmed COVID-19 (n=186), 22% with myocardial injury (n=41); and ruled out COVID-19 (n=247), 21.5% with myocardial injury (n=52). The confirmed and ruled out COVID-19 groups had a similar age, sex, and cardiovascular history. Mortality was significantly higher in the confirmed COVID-19 group than in the ruled out group (19.9% vs 5.3%, P <.001). In Cox multivariate regression analysis, cardiac troponin I was a predictor of mortality in both groups (confirmed COVID-19 group: HR, 3.54; 95%CI, 1.70-7.34; P=.001; ruled out COVID-19 group: HR, 5.57; 95%CI, 1.70-18.20; P=.004). The predictive model analyzed by ROC curves was similar in the 2 groups (P=.701), with AUCs of 0.808 in the confirmed COVID-19 group (0.750-0.865) and 0.812 in the ruled out COVID-19 group (0.760-0.864). CONCLUSIONS: Myocardial injury is detected in 1 in every 5 patients with confirmed or ruled out COVID-19 and predicts 30-day mortality to a similar extent in both circumstances.


Assuntos
COVID-19/mortalidade , Cardiomiopatias/mortalidade , SARS-CoV-2 , Troponina I/sangue , Idoso , COVID-19/sangue , COVID-19/complicações , COVID-19/diagnóstico , Teste de Ácido Nucleico para COVID-19/estatística & dados numéricos , Cardiomiopatias/sangue , Intervalos de Confiança , Feminino , Hospitalização/estatística & dados numéricos , Hospitais Universitários , Humanos , Unidades de Terapia Intensiva/estatística & dados numéricos , Pulmão/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Prognóstico , Curva ROC , Análise de Regressão , Estudos Retrospectivos , Fatores de Risco
14.
Rev Esp Cardiol (Engl Ed) ; 74(6): 502-509, 2021 Jun.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-32451223

RESUMO

INTRODUCTION AND OBJECTIVES: Release kinetics of high-sensitivity cardiac troponin (hs-cTn) T and I in patients with acute myocardial infarction (AMI) are incompletely understood. We aimed to assess whether hs-cTnT/I release in early AMI is near linear. METHODS: In a prospective diagnostic multicenter study the acute release of hs-cTnT and hs-cTnI within 1 and 2hours from presentation to the emergency department was quantified using 3 hs-cTnT/I assays in patients with suspected AMI. The primary endpoint was correlation between hs-cTn changes from presentation to 1 hour vs changes from presentation to 2hours, among all AMI patients and different prespecified subgroups. The final diagnosis was adjudicated by 2 independent cardiologists, based on serial hs-cTnT from the serial study blood samples and additional locally measured hs-cTn values. RESULTS: Among 2437 patients with complete hs-cTnT data, AMI was the adjudicated diagnosis in 376 patients (15%). For hs-cTnT, the correlation coefficient between 0- to 1-hour change and 0- to 2 hour change was 0.931 (95%CI, 0.916-0.944), P <.001. Similar findings were obtained with hs-cTnI (Architect) with correlation coefficients between 0- to 1-hour change and 0- to 2 hour change of 0.969 and hs-cTnI (Centaur) of 0.934 (P <.001 for both). Findings were consistent among type 1 and type 2 AMI and in the subgroup of patients presenting very early after chest pain onset. CONCLUSIONS: Patients presenting with early AMI showed a near linear release of hs-cTnT and hs-cTnI. This near linearity provides the pathophysiological basis for rapid diagnostic algorithms using 0- to 1-hour changes as surrogates for 0- to 2 hour or 0- to 3 hour changes. Registered at ClinicalTrials.gov (Identifier: NCT00470587).


Assuntos
Infarto do Miocárdio , Troponina T , Biomarcadores , Humanos , Cinética , Infarto do Miocárdio/diagnóstico , Estudos Prospectivos , Troponina I
15.
Pesqui. vet. bras ; 40(12): 1002-1009, Dec. 2020. tab, ilus
Artigo em Inglês | LILACS, VETINDEX | ID: biblio-1155035

RESUMO

Chronic kidney disease (CKD) is characterized by irreversible morphostructural lesions that can progressively evolve to chronic renal insufficiency and kidney failure. It is known that the heart and kidneys are closely related, and that communication between these organs occurs through a variety of pathways; subtle physiological changes in one of them are compensated by the other. Histopathological cardiac evaluation through routine staining presents a limitation to identify specific or discreet lesions in the cardiomyocytes. This study aimed to evaluate serum troponin levels in cats with CKD, associated with clinical and pathological findings, as well as to correlate the morphostructural cardiac lesions to determine their distribution through macroscopic and histological assessments and anti-cardiac troponin C (cTnC) immunohistochemistry (IHC). To this end, 20 cats (18 diagnosed with CKD and two controls) were selected. Anti-human cTnC IHC was conducted after necropsy and separation in eight regions of each collected heart. Heart fragments from two cats without CKD were used as controls. The anti-human cTnC antibody is useful in detecting cardiac lesions and has shown decreased expression in cardiomyocytes of cats with CKD. Serum troponin was above the reference values in 11/18 (61.11%) animals and decreased expression for the cTnC antibody was observed in individual cardiomyocytes in 9/18 (50%) animals. It was verified that the number of regions with decreased expression for the cTnC antibody in cardiomyocytes is significantly correlated with serum troponin. The anti-human cTnC antibody has been found effective in detecting cardiac lesions and has shown decreased expression in the cardiomyocytes of cats with CKD. Correlation was observed between increased serum cTnI and loss of immunoreactivity at anti-cTnC antibody IHC in cats with CKD, which proves damage to cardiomyocytes secondary to kidney disease.(AU)


A doença renal crônica (DRC) é caracterizada por lesões morfoestruturais irreversíveis, que podem evoluir progressivamente para insuficiência renal crônica e falência renal. Sabe-se que o coração e os rins mantêm estreita relação e a comunicação entre esses órgãos ocorre por uma variedade de vias; alterações fisiológicas sutis em um desses órgãos são compensadas pelo outro. A avaliação histopatológica cardíaca mediante a colorações rotineiras são limitadas para identificar lesões específicas ou discretas em cardiomiócitos. O presente trabalho teve como objetivos avaliar os níveis séricos de troponina em gatos com DRC, associados aos achados clínico-patológicos, bem como correlacionar as lesões cardíacas morfoestruturais, a fim de determinar a distribuição destas, por meio da avaliação macroscópica, histológica e imuno-histoquímica com anti-cTnC. Neste estudo foram selecionados 20 gatos (18 diagnosticados com DRC e 2 animais controle). Para a aplicação da técnica de imuno-histoquímica anti-troponina C humana, necropsias foram realizadas e cada coração coletado separadamente em 8 regiões. Fragmentos do coração de 2 gatos sem lesão cardíaca foram utilizados como controle. O anticorpo anti-TnC humano é útil na detecção de lesões cardíacas e apresentou expressão diminuída em cardiomiócitos de gatos com DRC. Em 11/18 animais (61,11%) a troponina sérica encontrava-se acima dos valores de referência e foram observadas diminuição da expressão para anticorpo-cTnC em cardiomiócitos individuais em 9/18 (50%). Notou-se que o número de regiões com diminuição da expressão para anticorpo-cTnC em cardiomiócitos está significativamente correlacionado com a troponina sérica. O anticorpo anti-TnC humano se mostrou eficaz para detectar lesões cardíacas e demonstrou diminuição da expressão nos cardiomiócitos de gatos com DRC. Houve correlação entre o aumento da CTnI sérica e perda da imunorretividade na avaliação imuno-histoquímica com anticorpo anti-TnC em gatos com DRC o que comprova danos em cardiomiócitos secundários a doença renal.(AU)


Assuntos
Animais , Gatos , Imuno-Histoquímica , Gatos/lesões , Coração , Rim , Nefropatias/diagnóstico , Nefropatias/patologia , Troponina
16.
Rev. argent. cardiol ; 88(6): 502-508, nov. 2020. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1251036

RESUMO

RESUMEN Introducción: Dado que los pacientes con diabetes tienen habitualmente niveles de troponina más elevados que la población general, nos propusimos evaluar el comportamiento del algoritmo de la Sociedad Europea de Cardiología que utiliza la medición de troponina de alta sensibilidad al ingreso y 1 hora después en estos pacientes. Material y métodos: Se evaluaron 1140 pacientes que consultaron por dolor torácico con electrocardiograma sin supradesnivel del segmento ST. El algoritmo estratifica los pacientes en tres grupos de riesgo: "externar", "observar" e "internar". Se valoró el comportamiento del algoritmo para el evento infarto a 30 d. Resultados: En total, 124 pacientes (10,8%) tenían diabetes. Ninguno de los clasificados como "externar" (40,3%) presentó infarto a 30 días. En los "internar" (23,4%), el evento se produjo en el 82,8%, mientras que en el grupo "observar" (36,3%), en el 6,8%. La sensibilidad y el valor predictivo negativo fueron similares entre pacientes con diabetes y sin esta (100% vs. 98,5% p = 0,865 y 100% vs. 99,8% p = 0,44), pero la proporción de pacientes para "externar" fue menor en diabéticos (40,3% vs. 72,1%, p <0,001). En cuanto a la precisión para "internar" pacientes, la especificidad fue menor en diabéticos, pero el valor predictivo positivo fue mayor (90,9% vs. 97,2%, p <0,001 y 83% vs. 76%, p <0,001). La proporción de pacientes para "internar" fue mayor en diabéticos (23% vs. 8,6%, p <0,001). Conclusiones: El uso del algoritmo en pacientes con diabetes mostró una alta sensibilidad y un alto valor predictivo negativo para "externar" comparable a la población general. En cuanto al grupo "internar", presentó menor especificidad, pero alto valor predictivo positivo. Esto lo transforma en una útil herramienta para la práctica diaria.


ABSTRACT Background: Patients with diabetes usually have higher troponin levels than the general population. Objective: The aim of our study was to evaluate the performance of the European Society of Cardiology algorithm which uses high sensitivity cardiac troponin levels on admission and after 1 hour in these patients. Methods: A total of 1,140 patients with chest pain and ECG without ST-segment elevation were evaluated. The algorithm stratifies patients in three risk groups: rule-out, observe and rule-in. We evaluated the performance of the algorithm to predict myocardial infarction at 30 days. Results: A total of 124 patients (10.8%) had diabetes. None of the patients in the rule-out group (40.3%) presented myocardial infarction at 30 days. In the rule-in group (23.4%), the event occurred in 82.8% of cases and in 6.8% in the observe group (36.3%). Sensitivity and negative predictive value were similar in patients with and without diabetes (100% vs. 98.5%, p= 0.865 and 100% vs. 99.8%, p=0.44), but the proportion of patients in the rule-out group was lower in diabetics (40.3% vs. 72.1%, p<0.001). The accuracy of the algorithm to rule in patients was evaluated by its specificity which was lower in diabetics, but the positive predictive value was greater (90.9% vs. 97.2%, p<0.001 and 83% vs. 76%, p<0.001). The proportion of patients in the rule-in group was higher in diabetics (23% vs. 8.6%, p<0.001). Conclusion: The use of the algorithm in patients with diabetes revealed high sensitivity and negative predictive value to rule out, which was similar to that of the general population. Regarding the rule-in group, it had lower specificity but high positive predictive value. This performance makes the algorithm a useful tool for daily practice.

17.
Arq. bras. cardiol ; 115(4): 620-627, out. 2020. tab, graf
Artigo em Português | Sec. Est. Saúde SP, LILACS, Sec. Est. Saúde SP | ID: biblio-1131355

RESUMO

Resumo Fundamento: Os efeitos da caminhada de longa distância sobre o sistema cardiovascular são pouco estudados. Objetivos: O objetivo geral deste estudo foi verificar esses efeitos sobre o comportamento da função diastólica e dos biomarcadores cardíacos CK-MB (massa), troponina T e NT-proBNP em atletas amadores. Método: Este estudo longitudinal realizado em 2015 avaliou os participantes nas 5 etapas seguintes: A0 (basal) antes de iniciar o percurso, e as demais, A1, A2, A3 e A4 ao final de cada dia, totalizando 244,7 km. Em todas as etapas foram dosados os biomarcadores NT-proBNP, CK-MB (massa) e troponina T. Realizou-se ecocardiograma para análise das ondas E, A e E'. Adotado p < 0,05 como significativo. Resultados: Foram avaliados 25 participantes com média de idade de 46 ± 10,5 anos e índice de massa corporal de 20,2 ± 2,3 kg/m2. Encontrou-se aumentos dos valores de NT-proBNP de A0 para A1, A2, A3 e A4 (p < 0,001), CK-MB (massa) de A0 para A2 (p < 0,001) e da onda E' de A0 para A1, A2, A3 e A4 (p < 0,001). Foram identificadas correlações entre os seguintes: CK-MB (massa) e troponina T (A1: r = 0,524, p = 0,010; A4: r = 0,413, p = 0,044); CK-MB (massa) e NT-proBNP (A4: r = 0,539, p = 0,006); e E/A e E' (A0: r = 0,603, p < 0,001; A1: r = 0,639, p < 0,001; A4: r = 0,593, p = 0,002); e correlação negativa entre CK-MB (massa) com E/A (A1: r = −0,428, p = 0,041). Conclusão: Os efeitos da atividade física intensa, prolongada e intercalada foram verificados a partir das variações significativas no comportamento da CK-MB (massa), NT-proBNP e E'. Apesar das alterações encontradas, não houve critérios sugestivos de dano ao miocárdio.


Abstract Background: The effects of long-distance walking on the cardiovascular system have been little studied. Objectives: The general objective of this study was to verify these effects on the behavior of diastolic function and the cardiac biomarkers CK-MB (mass), troponin T, and NT-proBNP, in amateur athletes. Method: This longitudinal study, conducted in 2015, evaluated participants during the following 5 stages: E0 (baseline) before starting the trajectory and the others, E1, E2, E3, and E4, at the end of each day, totaling 244.7 km. At all stages, the biomarkers NT-proBNP, CK-MB (mass), and troponin T were measured. Echocardiogram was performed to analyze the E, A and E' waves. P < 0.05 was adopted as significant. Results: The study evaluated 25 participants, with an average age of 46 ± 10.5 years and body mass index of 20.2 ± 2.3 kg/m2. Increased values were found for NT-proBNP from E0 to E1, E2, E3, and E4 (p < 0.001), CK-MB (mass) from E0 to E2 (p < 0.001), and E' wave from E0 to E1, E2, E3, and E4 (p < 0.001). Positive correlations were identified between the following: CK-MB (mass) and troponin T (E1: r = 0.524, p = 0.010; E4: r = 0.413, p = 0.044); CK-MB (mass) and NT-proBNP (E4: r = 0.539, p = 0.006); and E/A and E' (E0: r = 0.603, p < 0.001; E1: r = 0.639, p < 0.001; E4: r = 0.593, p = 0.002). A negative correlation was found between CK-MB (mass) and E/A (E1: r = −0.428, p = 0.041). Conclusion: The effects of intense, prolonged, and interspersed physical activity were verified based on significant variations in the behavior of CK-MB (mass), NT-proBNP, and the E' wave. Notwithstanding the alterations found, there were no criteria suggestive of myocardial damage


Assuntos
Humanos , Adulto , Pessoa de Meia-Idade , Caminhada , Peptídeo Natriurético Encefálico , Fragmentos de Peptídeos , Biomarcadores , Estudos Longitudinais , Troponina T , Creatina Quinase Forma MB
19.
Arq. bras. cardiol ; 115(4): 660-666, out. 2020. tab, graf
Artigo em Português | Sec. Est. Saúde SP, LILACS, Sec. Est. Saúde SP | ID: biblio-1131337

RESUMO

Resumo Fundamento: A COVID-19 causa grave acometimento pulmonar, porém o sistema cardiovascular também pode ser afetado por miocardite, insuficiência cardíaca e choque. A elevação de biomarcadores cardíacos tem sido associada a um pior prognóstico. Objetivos: Avaliar o valor prognóstico da Troponina T (TnT) e do peptídeo natriurético tipo B (BNP) em pacientes internados por Covid-19. Métodos: Amostra de conveniência de pacientes hospitalizados por COVID-19. Foram coletados dados dos prontuários com o objetivo de avaliar a relação da TnT e o BNP medidos nas primeiras 24h de admissão com o desfecho combinado (DC) óbito ou necessidade de ventilação mecânica. Análise univariada comparou os grupos com e sem DC. Modelo multivariado de Cox foi utilizada para determinar preditores independentes do DC. Resultados: Avaliamos 183 pacientes (idade=66,8±17 anos, sendo 65,6% do sexo masculino). Tempo de acompanhamento foi de 7 dias (1 a 39 dias). O DC ocorreu em 24% dos pacientes. As medianas de TnT e BNP foram 0,011 e 0,041 ng/dl (p<0,001); 64 e 198 pg/dl (p<0,001) respectivamente para os grupos sem e com DC. Na análise univariada, além de TnT e BNP, idade, presença de doença coronariana, saturação de oxigênio, linfócitos, dímero-D, proteína C reativa titulada (PCR-t) e creatinina, foram diferentes entre os grupos com e sem desfechos. Na análise multivariada boostraped apenas TnT (1,12[IC95%1,03-1,47]) e PCR-t (1,04[IC95%1,00-1,10]) foram preditores independentes do DC. Conclusão: Nas primeiras 24h de admissão, TnT, mas não o BNP, foi marcador independente de mortalidade ou necessidade de ventilação mecânica invasiva. Este dado reforça ainda mais a importância clínica do acometimento cardíaco da COVID-19. (AArq Bras Cardiol. 2020; 115(4):660-666)


Abstract Background: COVID-19 causes severe pulmonary involvement, but the cardiovascular system can also be affected by myocarditis, heart failure and shock. The increase in cardiac biomarkers has been associated with a worse prognosis. Objectives: To evaluate the prognostic value of Troponin-T (TNT) and natriuretic peptide (BNP) in patients hospitalized for Covid-19. Methods: This was a convenience sample of patients hospitalized for COVID-19. Data were collected from medical records to assess the association of TnT and BNP measured in the first 24 hours of hospital admission with the combined outcome (CO) of death or need for mechanical ventilation. Univariate analysis was used to compare the groups with and without the CO. Cox's multivariate model was used to determine independent predictors of the CO. Results: We evaluated 183 patients (age = 66.8±17 years, 65.6% of which were males). The time of follow-up was 7 days (range 1 to 39 days). The CO occurred in 24% of the patients. The median troponin-T and BNP levels were 0.011 and 0.041ng/dL (p <0.001); 64 and 198 pg/dL (p <0.001), respectively, for the groups without and with the CO. In the univariate analysis, in addition to TnT and BNP, age, presence of coronary disease, oxygen saturation, lymphocytes, D-dimer, t-CRP and creatinine, were different between groups with and without outcomes. In the bootstrap multivariate analysis, only TnT (1.12 [95% CI 1.03-1.47]) and t-CRP (1.04 [95% CI 1.00-1.10]) were independent predictors of the CO. Conclusion: In the first 24h of admission, TnT, but not BNP, was an independent marker of mortality or need for invasive mechanical ventilation. This finding further reinforces the clinical importance of cardiac involvement in COVID-19. (Arq Bras Cardiol. 2020; 115(4):660-666)


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Pneumonia Viral/diagnóstico , Troponina/sangue , Infecções por Coronavirus/diagnóstico , Peptídeo Natriurético Encefálico/sangue , Pneumonia Viral/mortalidade , Prognóstico , Biomarcadores/sangue , Sistema Cardiovascular/fisiopatologia , Sistema Cardiovascular/virologia , Infecções por Coronavirus , Infecções por Coronavirus/mortalidade , Pandemias , Betacoronavirus
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...